IPC 7 English version
  A61K 33/00 - A61K 38/58  
A61K03900-A61K12300
 

SECTION A – HUMAN NECESSITIES


A 61MEDICAL OR VETERINARY SCIENCE; HYGIENE


A 61 KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N)


39/

00Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N 33/53) [2]

Notes

(1)Groups A61K 39/002 to A61K 39/295 cover preparations containing protozoa, bacteria, viruses, or subunits thereof, e.g. membrane parts.  [3]

(2)Preparation of antigen or antibody compositions is also classified in subclass C12N, if the step of cultivating the micro-organism is of interest.  [3]

39/

002.Protozoa antigens  [3]

39/

005..Trypanosoma antigens  [3]

39/

008..Leishmania antigens  [3]

39/

012..Coccidia antigens  [3]

39/

015..Hemosporidia antigens, e.g. Plasmodium antigens  [3]

39/

018...Babesia antigens, e.g. Theileria antigens  [3]

39/

02.Bacterial antigens  [2]

39/

04..Mycobacterium, e.g. Mycobacterium tuberculosis  [2,3]

39/

05..Corynebacterium; Propionibacterium  [3]

39/

07..Bacillus  [3]

39/

08..Clostridium, e.g. Clostridium tetani  [2]

39/

085..Staphylococcus  [3]

39/

09..Streptococcus  [3]

39/

095..Neisseria  [3]

39/

10..Brucella; Bordetella, e.g. Bordetella pertussis  [2,3]

39/

102..Pasteurella; Haemophilus  [3]

39/

104..Pseudomonas  [3]

39/

106..Vibrio; Campylobacter  [3]

39/

108..Escherichia; Klebsiella  [3]

39/

112..Salmonella; Shigella  [3]

39/

114..Fusobacterium  [3]

39/

116..Polyvalent bacterial antigens  [3]

39/

118.Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci  [3]

39/

12.Viral antigens  [2]

39/

125..Picornaviridae, e.g. calicivirus  [3]

39/

13...Poliovirus  [3]

39/

135...Foot-and-mouth disease virus  [3]

39/

145..Orthomyxoviridae, e.g. influenza virus  [3]

39/

15..Reoviridae, e.g. calf diarrhea virus  [3]

39/

155..Paramyxoviridae, e.g. parainfluenza virus  [3]

39/

165...Mumps or measles virus  [3]

39/

17...Newcastle disease virus  [3]

39/

175...Canine distemper virus  [3]

39/

187..Hog cholera virus  [3]

39/

193..Equine encephalomyelitis virus  [3]

39/

20..Rubella virus  [2]

39/

205..Rhabdoviridae, e.g. rabies virus  [3]

39/

21..Retroviridae, e.g. equine infectious anemia virus  [3]

39/

215..Coronaviridae, e.g. avian infectious bronchitis virus  [3]

39/

225...Porcine transmissible gastroenteritis virus  [3]

39/

23..Parvoviridae, e.g. feline panleukopenia virus  [3]

39/

235..Adenoviridae  [3]

39/

245..Herpetoviridae, e.g. herpes simplex virus  [3]

39/

25...Varicella-zoster virus  [3]

39/

255...Marek's disease virus  [3]

39/

265...Infectious rhinotracheitis virus  [3]

39/

27...Equine rhinopneumonitis virus  [3]

39/

275..Poxviridae, e.g. avipoxvirus  [3]

39/

285...Vaccinia virus or variola virus  [3]

39/

29..Hepatitis virus  [3]

39/

295..Polyvalent viral antigens (vaccinia virus or variola virus A61K 39/285); Mixtures of viral and bacterial antigens  [3]

39/

35.Allergens  [3]

39/

36..from pollen  [2,3]

39/

38.Antigens from snakes  [2]

39/

385.Haptens or antigens, bound to carriers  [3]

39/

39.characterised by the immunostimulating additives, e.g. chemical adjuvants  [3]

39/

395.Antibodies (agglutinins A61K 38/36); Immunoglobulins; Immune serum, e.g. antilymphocytic serum  [3]

39/

40..bacterial  [2,3]

39/

42..viral  [2,3]

39/

44..Antibodies bound to carriers  [2,3]


41/

00Medicinal preparations obtained by treating materials with wave energy or particle radiation (A61K 31/59 takes precedence; electric discharge tubes H01J) [2]


45/

00Medicinal preparations containing active ingredients not provided for in groups A61K 31/00 to A61K 41/00  [2,6]

 

45/

05(covered by A61K 45/00)

45/

06.Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca  [2]

45/

08.Mixtures of an active ingredient and an auxiliary substance neither being chemically characterised, e.g. antihistaminicum and surface active substance  [2]


47/

00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives  [2]

47/

02.Inorganic compounds  [5]

47/

04..Non-metals; Compounds thereof  [5]

47/

06.Organic compounds  [5]

47/

08..containing oxygen  [5]

47/

10...Alcohols; Phenols; Salts thereof  [5]

47/

12...Carboxylic acids; Salts or anhydrides thereof  [5]

47/

14...Esters of carboxylic acids  [5]

47/

16..containing nitrogen  [5]

47/

18...Amines; Quaternary ammonium compounds  [5]

47/

20..containing sulfur  [5]

47/

22..Heterocyclic compounds  [5]

47/

24..containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen or sulfur  [5]

47/

26..Carbohydrates  [5]

47/

28..Steroids  [5]

47/

30.Macromolecular compounds  [5]

47/

32..Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds  [5]

47/

34..Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds  [5]

47/

36..Polysaccharides; Derivatives thereof  [5]

47/

38...Cellulose; Derivatives thereof  [5]

47/

40...Cyclodextrins; Derivatives thereof  [5]

47/

42..Proteins; Polypeptides; Degradation products thereof; Derivatives thereof  [5]

47/

44.Oils, fats or waxes according to more than one of groups A61K 47/02 to A61K 47/42  [5]

47/

46.Ingredients of undetermined constitution or reaction products thereof  [5]

47/

48.the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates  [5]


48/

00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy  [5]


49/

00Preparations for testing in vivo  [3]

49/

04.X-ray contrast preparations  [3]

49/

06.Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations [7]

 

49/

08..characterised by the carrier [7]

 

49/

10...Organic compounds [7]

 

49/

12....Macromolecular compounds [7]

 

49/

14....Peptides, e.g. proteins [7]

 

49/

16.....Antibodies; Immunoglobulins; Fragments thereof [7]

 

49/

18..characterised by a special physical form, e.g. emulsions, microcapsules, liposomes [7]

 

49/

20..containing free radicals [7]

 

49/

22.Echographic preparations; Ultrasound imaging preparations [7]

 

51/

00Preparations containing radioactive substances for use in therapy or testing in vivo  [6]

Note

 In this group, it is desirable to add the indexing codes of groups A61K 101:00 to A61K 123:00. The indexing codes should be unlinked.  [6]

51/

02.characterised by the carrier  [6]

51/

04..Organic compounds  [6]

51/

06...Macromolecular compounds  [6]

51/

08...Peptides, e.g. proteins  [6]

51/

10....Antibodies or immunoglobulins; Fragments thereof  [6]

51/

12.characterised by a special physical form, e.g. emulsion, microcapsules, liposomes  [6]


Indexing scheme associated with group A61K 51/00, relating to the nature or the activity of the radioactive substance. The indexing codes should be unlinked.  [6]

Note

 Attention is drawn to Chapter IV of the Guide which sets forth the rules concerning the application and presentation of the different types of indexing code.  [6]


101:

00Radioactive non-metals  [6]

101:

02.Halogens  [6]


103:

00Radioactive metals  [6]

103:

10.Technetium; Rhenium  [6]

103:

20.Indium  [6]

103:

30.Rare earths  [6]

103:

32..Yttrium  [6]

103:

34..Gadolinium  [6]

103:

36..Ytterbium  [6]

103:

40.Actinides  [6]


121:

00Preparations for use in therapy  [6]


123:

00Preparations for testing in vivo  [6]

  A61K 33/00 - A61K 38/58